Moonlight Therapeutics, Inc. announced the initiation of SURVEYOR, a Phase I clinical trial, evaluating MOON101 for the treatment of peanut allergy, marking the program’s transition into clinical-stage development.

Moonlight is developing MOON101 as a treatment for peanut allergy and has received clearance from the FDA to proceed clinical testing of MOON101 in peanut allergic adults and children as well as new funding.

Moonlight Therapeutics, a biotechnology company, has received a multi-million dollar clinical trial grant from the NIH to evaluate its treatment, MOON101, for peanut allergy in peanut allergic children and adults.

A five-minute weekly dose of peanut protein through the skin, delivered by a novel microneedle technology, was superior in desensitizing peanut-allergic mice compared to administering the protein through a skin patch, a new study has found.

Moonlight Therapeutics, Inc., announced today it has completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of MOON101 for the treatment of peanut allergy.

Moonlight Therapeutics, Inc., announced today funding from a Phase 2 Small Business grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support the company’s preclinical development of a targeted peanut allergy treatment

Moonlight Therapeutics, Inc., a biotechnology company developing treatments for food allergies, announced today the receipt of $2.5 million in funding for preclinical studies and product development that will enable preparations for a clinical trial for its lead program in peanut allergy.